the fourth thing did was to say that could come from pharmaceutical companies should not be received the general public without them asking for it first
The fourth thing we did was to say that any information that could come from pharmaceutical companies should not be received by patients or the general public without them asking for it first.
The fourth thing did was to say that could come from pharmaceutical companies should not be received the general public without them asking for it first.